Home › Compare › FLRAF vs ABBV
FLRAF yields 2.44% · ABBV yields 3.12%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, FLRAF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of FLRAF + ABBV for your $10,000?
Essentra plc provides essential components and solutions worldwide. The Components division manufactures and distributes plastic injection molded, vinyl dip-molded, and metal items for equipment manufacturing, automotive, fabrication, electronics, and construction industries; and component solutions comprising caps and plugs, wire and cable management products, flange protection products, knobs, handles and grips, PCB and electronics hardware, and tools and precision instruments for a range of applications and industries that are used in protection and finish products. The Packaging division provides cartons, leaflets, self-adhesive labels, and printed foils for use in blister packs; and packaging and authentication solutions to the health and personal care sectors. The Filter division offers filters and packaging solutions to the roll own segments; analytical laboratory services; and e-cigarette and heat not burn solutions for next generation products. The company was formerly known as Filtrona plc and changed its name to Essentra plc in June 2013. Essentra plc was incorporated in 2005 and is based in Milton Keynes, the United Kingdom.
Full FLRAF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.